Personalized medicine: What’s in it for rare diseases?

Sebastian Schee Genannt Halfmann, Laura Mählmann, Lada Leyens, Matthias Reumann, Angela Brand

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

Personalised Medicine has become a reality over the last years. The emergence of ‘omics’ and big data has started revolutionizing healthcare. New ‘omics’ technologies lead to a better molecular characterization of diseases and a new understanding of the complexity of diseases. The approach of PM is already successfully applied in different healthcare areas such as oncology, cardiology, nutrition and for rare diseases. However, health systems across the EU are often still promoting the ‘one-size fits all’ approach, even if it is known that patients do greatly vary in their molecular characteristics and response to drugs and other interventions. To make use of the full potentials of PM in the next years ahead several challenges need to be addressed such as the integration of big data, patient empowerment, translation of basic to clinical research, bringing the innovation to the market and shaping sustainable healthcare systems.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages387-404
Number of pages18
DOIs
Publication statusPublished - 01-01-2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1031
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Schee Genannt Halfmann, S., Mählmann, L., Leyens, L., Reumann, M., & Brand, A. (2017). Personalized medicine: What’s in it for rare diseases? In Advances in Experimental Medicine and Biology (pp. 387-404). (Advances in Experimental Medicine and Biology; Vol. 1031). Springer New York LLC. https://doi.org/10.1007/978-3-319-67144-4_22